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81.4), and they were willing to pay $49.6/month (95%CI 44.8-54.3). Multivariate
analysis identified race as a predictor ofWTP:Whites reportedmeanWTP $18.2 (CI
8.0-28.3) less than African Americans. CONCLUSIONS: After completing a two year
trial, themajority of participants in both groups were willing to pay similar rates to
other commercially available weight loss products. The surprising racial differ-
ences in WTP seen in this high SES group need to be further examined when trial
weight outcomes are available. After a free or fully subsidized period, it might be
reasonable to implement a direct to consumer or cost sharingmechanism to better
translate effective evidence-based weight loss interventions into practice.
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OBJECTIVES: To evaluate the My Health Matters! (MHM) program, a multifaceted
workplace intervention relying on education and awareness, early detection and
disease management with a focus on risk factors for metabolic syndrome.
METHODS: The MHM program was offered to 2,000 public servants working in
more than 30worksites in British Columbia, Canada. TheMHMprogram included a
health risk assessment combined with an opportunity to attend an on-site screen-
ing and face-to-face call back visits and related on-site educational programs. Clin-
ical and economic outcomes were collected over time in this one-year prospective
study coupled with administrative and survey data. RESULTS: Forty three per cent
of employees (N857) completed the online HRA and 23 per cent (N447) attended
the initial clinical visit with the nurse. Risk factors for metabolic syndrome were
identified inmore than half of those attending the clinical visit. The number of risk
factors significantly decreased by 15 per cent over sixmonths (N141). The cost per
employee completing the HRAwas $205 while the cost per employee attending the
initial clinical visit was $394. Eighty-two per cent of employees would recommend
the program to other employers. CONCLUSIONS: This study supports that work-
place interventions are feasible, sustainable and valued by employees. As such,
this study provides a new framework for implementing and evaluating workplace
interventions focussing on metabolic disorders.
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OBJECTIVES:One third of US adults are obese and it is projected that by 2030 half of
US adults will be obese. The study aimed to identify predictors of obesity treatment
in ambulatory care settings. METHODS: National Ambulatory Care Survey
(NAMCS) 2006-07, a cross-sectional nationally representative data,was used for the
study. A retrospective cohort study design was employed; obese adults, age20
years and BMI  30 kg/m2 or having obesity diagnosis (ICD-9-CM code: 278), were
include in the cohort. Obesity treatment included either obesity counseling (diet/
nutrition, exercise, weight reduction) or pharmacotherapy (anorexiant or lipase
inhibitor). Predisposing, enabling and need characteristics as per Anderson’s be-
havioral model were included as predictor variables. Descriptive statistics and
multivariate logistic regression were conducted to identify obesity treatment pre-
dictors while preserving complex survey design of NAMCS. RESULTS: Total of 214
million visits occurred during 2006-07 by obese adults; of which, 32.66% visits re-
sulted in obesity treatment. Factors predicting obesity treatment were reason for
visit, preventive visit (OR2.23; 95% CI1.50-3.32) and chronic visit (OR1.93; 95%
CI1.46-2.55) compared to acute visit; time spent with physician, 24 minutes
(OR2.67; 95% CI1.81-3.94) and 13-24 minutes (OR1.89; 95% CI1.26-2.82) com-
pared to 0-12 minutes; high comorbidity (OR1.46; 95% CI1.13-1.89); morbidly
obese adults i.e. BMI 40 (OR1.88; 95% CI1.52-2.34) and visit to primary care
physician (OR2.38; 95% CI1.69-2.36) compared to specialist. Older adults aged
65 (OR0.98; 95% CI0.97-0.99) and smokers (OR0.52; 0.39-0.69) had less likeli-
hood of receiving obesity treatment. Gender, race, region and insurance status
were not significant predictors of obesity treatment. CONCLUSIONS: Only one
third visits resulted into obesity treatment. Reason for visit, time spent with phy-
sician, comorbidity, BMI 40, provider specialty, age and nonsmoking status were
significant predictors of obesity treatment. Future research should identify reasons
for these observed differences and efforts should be taken to deliver equitable
access.
PSY50
PRESCRIPTION MONITORING PROGRAMS’ UTILIZATION
Fleming ML, Barner JC, Chandwani H, Okoro T, Weber S
University of Texas at Austin, Austin, TX, USA
OBJECTIVES: Prescription monitoring programs (PMPs) have been purported to be
an effective tool to combat prescription drug abuse. However, utilization rates of
PMP data by health care practitioners is relatively low. The objectives of this study
were to determine 1) the rates of PMP request by professional affiliation per 100,000
population; 2) determine differences in rates of requests based on PMP accessibility
(online vs. other); 3) if differences exist in professional affiliation rates of requests
per 100,000 population by PMP housing agency (law enforcement agency vs. health
profession); 4) collect data on annual operating costs of PMPs per 100,000
population. METHODS: This was a cross sectional study employing a web based
survey. The survey was emailed to the 33 operational state PMP administrators
during December 2010. Descriptive statistics were used to describe PMP structure
and utilization rates. T-tests and Manova were used to determine the associations
between rates of request and PMP features. RESULTS: The preliminary response
rate was 27%. Prescribers accessed PMP datamost frequently among all authorized
users,mean requests 1,764, SD3,106. Pharmacistmean requests 171, SD220.
TheT-tests results indicate that there is a statistically significant lower request rate
for PMP datawhen housed by law enforcement administration, (t 2.5, p .04). On
average PMP annual costs were $8,146 per 100,000 population. CONCLUSIONS:
Based on preliminary results, the PMP housing entity has an impact on health care
professionals’ utilization. Online accessibility is also associatedwith an increase in
requested data reports by health care professionals. More research is needed to
determine other factors associated with PMP utilization by prescribers and phar-
macists.
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OBJECTIVES:Thepurpose of this studywas to evaluate the effectiveness of the new
FDA mandated over-the-counter (OTC) acetaminophen organ-specific label warn-
ings, on: 1) consumer risk perception of liver damage associated with acetamino-
phen use and 2) behavioral intention to perform protective behavior.METHODS: In
this within-subject experimental study, English-speaking adults visiting OTC seg-
ments of selected pharmacy stores in Houston were conveniently recruited. Par-
ticipants were randomly exposed to both old and new label warnings and their
respective risk perception (measured on a visual analog scale, 0%, no risk, – 100%,
extreme risk) and behavioral intention (measured on a 7-point Likert scale) were
recorded using a validated, self-administered questionnaire. Descriptive statistics
and non-parametric Wilcoxon signed-rank tests were performed using SAS statis-
tical software (v9.2) at a priori significance level of 0.05. RESULTS: A total of 200
responses were collected with a response rate of 56.81%. Mean age of the sample
was 42.68 (SD 15.30) years; 48.5% of respondents weremale and 52.7%were whites.
Amajority of respondents (74.4%) were not aware of the newwarnings; however, a
majority (67.8%) had prior knowledge of the risk. The mean risk perception score
for the new label warnings was found to be significantly higher (72.2% vs. 65.9%,
p.0001) as compared to that of the old label warnings. Similarly, the average
intention score for the new labelwarningswas found to be significantly higher (5.06
vs. 4.86, p.0001) than that of the old label warnings.CONCLUSIONS: The results of
this study indicate that the new label warnings mandated by FDAmay be effective
in improving consumer risk perception of potential liver damage andmay encour-
age protective behavior. Future studies are essential to identify the impact as ac-
tual changes in consumer behavior and subsequent reduction in acetaminophen-
related morbidity and mortality.
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OBJECTIVES: To describe the potential for drug-drug interactions (DDIs) among
patients with neck and back pain diagnoses categorized into neuropathic (NEURO),
neuropathic and nociceptive(MIXED), nociceptive only (NOCI)or osteoarthritis (OA)
cohorts.METHODS:The PharMetrics USNationalmanaged care databasewas used
to identify commercially insured patients 18 to 63 years of age with at least one
claim for an opioid analgesic and a pre-existing study-related diagnosis, who were
continuously eligible for services from 9/1/2006-8/31/2008. Patients who had nurs-
ing home care claims, drug/alcohol abuse, malignancy, and spine procedures, or
pregnancy-related diagnoses were excluded. Over the 2-year study period, the fre-
quency of patients with at least 10 days of simultaneous availability of pain or
pain-related prescriptions and medications that are known inhibitors or inducers
of the cytochrome P450 (CYP) metabolic pathway was examined. RESULTS: The
analysis identified 2,375 NEURO, 37,019MIXED, 39,496 NOCI, and 6,124 OA patients.
A high prevalence of coexisting medical conditions was found in all cohorts with
40%-74% of patients having diagnoses in at least 8 different disease categories.
Based on the 10-day simultaneous drug availability criterion, the potential for DDIs
were identified in 26% of all patients during the 2-year observation period. This
percentage was highest in the MIXED cohort (31%) and lowest in the NOCI cohort
(20%). Overall, potential inhibitor interactions were found in 20% of patients and
potential inducer interactions were found in 11%. The CYP-2D6 substrates trama-
dol and oxycodone were the most frequent potential inhibitor interactions (5.6%
and 5.9% of patients, respectively). Potential inducer DDIs were most commonly
found in the CYP-1A2 pathway (8% of patients). CONCLUSIONS: Potential DDIs are
common among patients taking pain medication. Coexisting medical conditions
and their treatment, and variations in the metabolism of different pain medica-
tions contribute to the complexity of selecting analgesics thatwould be expected to
effectively treat pain.
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